ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,629.00
0.00%
S&P ASX All Technology
3,016.30
0.00%
Brent Oil
83.225
0.56%
US Dollar vs AUD
1.51145
-0.17%
Bitcoin
64,125.97
0.37%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Coeptis Therapeutics Holdings Inc (COEP)

  7. Coeptis Therapeutics Holdings Inc (COEP) News

COEP

Coeptis Therapeutics (COEP)

Coeptis Therapeutics Holdings Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:COEP
DateTimeSourceHeadlineSymbolCompany
02/05/202422:47PR Newswire (US)Coeptis Therapeutics Announces Poster Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 27th Annual MeetingNASDAQ:COEPCoeptis Therapeutics Holdings Inc
02/04/202423:47PR Newswire (US)Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor's Distinguished Research AwardNASDAQ:COEPCoeptis Therapeutics Holdings Inc
27/02/202401:00PR Newswire (US)Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NKNASDAQ:COEPCoeptis Therapeutics Holdings Inc
07/02/202423:30PR Newswire (US)Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral InfectionsNASDAQ:COEPCoeptis Therapeutics Holdings Inc
04/01/202423:30PR Newswire (US)Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024NASDAQ:COEPCoeptis Therapeutics Holdings Inc
01/11/202300:01PR Newswire (US)Coeptis Therapeutics Announces Research Demonstrating the Potential of SNAP-CAR T-cells to Reduce Tumor Burden and Growth in HER2 and CD20 Expressing Cancers Will be Presented at SITC 2023NASDAQ:COEPCoeptis Therapeutics Holdings Inc
24/10/202323:30PR Newswire (US)Coeptis Therapeutics Announces $2 Million Private PlacementNASDAQ:COEPCoeptis Therapeutics Holdings Inc
11/10/202322:30PR Newswire (US)Coeptis Therapeutics Expands License Agreement with University of Pittsburgh to Include SNAP-CAR NK Cell TechnologyNASDAQ:COEPCoeptis Therapeutics Holdings Inc
10/10/202300:15PR Newswire (US)Coeptis Therapeutics to Participate in Panel at the BioFlorida Conference Discussing Emerging Cell and Gene TherapiesNASDAQ:COEPCoeptis Therapeutics Holdings Inc
04/10/202322:30PR Newswire (US)Coeptis Therapeutics Announces Research Involving SNAP-CAR Accepted for Presentation at the Society for Immunotherapy of Cancer's 38th Annual MeetingNASDAQ:COEPCoeptis Therapeutics Holdings Inc
27/09/202321:30PR Newswire (US)Coeptis Therapeutics to Present at the 2023 Cell & Gene Meeting on the MesaNASDAQ:COEPCoeptis Therapeutics Holdings Inc
14/09/202321:30PR Newswire (US)Coeptis Therapeutics Provides Safety and Dosing Update from Phase 1 Trials Investigating DVX201 in Relapsed/Refractory AML or High Risk MDS and Hospitalized COVID-19 InfectionNASDAQ:COEPCoeptis Therapeutics Holdings Inc
11/09/202321:30PR Newswire (US)Coeptis Therapeutics Announces Deverra Therapeutics Has Received Two Life Science Start-Up and Development Awards and Associated Grant from Washington's Cancer Research EndowmentNASDAQ:COEPCoeptis Therapeutics Holdings Inc
31/08/202303:00PR Newswire (US)Coeptis Therapeutics Appoints Colleen Delaney, MD, as Chief Scientific and Medical OfficerNASDAQ:COEPCoeptis Therapeutics Holdings Inc
17/08/202321:30PR Newswire (US)Coeptis Therapeutics Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage Assets from Deverra TherapeuticsNASDAQ:COEPCoeptis Therapeutics Holdings Inc
01/08/202322:00PR Newswire (US)Coeptis Therapeutics Files FDA 513(g) Submission for CD38 In Vitro Companion DiagnosticNASDAQ:COEPCoeptis Therapeutics Holdings Inc
17/06/202306:00PR Newswire (US)Coeptis Therapeutics Holdings, Inc. Announces Closing of $3.5 Million Underwritten OfferingNASDAQ:COEPCoeptis Therapeutics Holdings Inc
14/06/202323:28PR Newswire (US)Coeptis Therapeutics Holdings, Inc. Announces Pricing of $3.5 Million Underwritten OfferingNASDAQ:COEPCoeptis Therapeutics Holdings Inc
09/06/202321:00PR Newswire (US)Coeptis Therapeutics Receives Approval to Transfer to The Nasdaq Capital MarketNASDAQ:COEPCoeptis Therapeutics Holdings Inc
17/05/202322:30PR Newswire (US)Coeptis Therapeutics Appoints Brian Cogley as Chief Financial OfficerNASDAQ:COEPCoeptis Therapeutics Holdings Inc
11/05/202305:00PR Newswire (US)Coeptis Therapeutics' SNAP-CAR Technology Platform for Programmable Antigen Targeting Featured in Peer-Reviewed Article in Nature CommunicationsNASDAQ:COEPCoeptis Therapeutics Holdings Inc
18/04/202321:30PR Newswire (US)Coeptis Therapeutics Signs Agreement to Acquire Allogeneic Immuno-Oncology NK Platform in Phase 1 Clinical Trials from Deverra TherapeuticsNASDAQ:COEPCoeptis Therapeutics Holdings Inc
30/03/202300:45PR Newswire (US)Coeptis Therapeutics Secures Exclusive Rights to Negotiate to Acquire Transformational Cell Therapy Platform to Enable Potent Combinatorial Immuno-Oncology Treatment StrategiesNASDAQ:COEPCoeptis Therapeutics Holdings Inc
21/03/202322:00PR Newswire (US)Coeptis Therapeutics' SNAP-CAR Technology Platform Highlighted in Peer-Reviewed Article in Translational MedicineNASDAQ:COEPCoeptis Therapeutics Holdings Inc
08/02/202300:00PR Newswire (US)Coeptis Therapeutics and ShareIntel Enter Shareholder Service Agreement, Targeting Illegal Short SellingNASDAQ:COEPCoeptis Therapeutics Holdings Inc
01/02/202300:45PR Newswire (US)Coeptis Therapeutics Enters into Sponsored Research Agreement with the University of Pittsburgh to Advance SNAP-CAR Development ProgramNASDAQ:COEPCoeptis Therapeutics Holdings Inc
22/11/202223:00PR Newswire (US)Coeptis Therapeutics Engages IQVIA to Support SNAP-CAR Development ProgramNASDAQ:COEPCoeptis Therapeutics Holdings Inc
15/11/202223:00PR Newswire (US)Coeptis Therapeutics Holdings to Ring the Nasdaq Stock Market Opening BellNASDAQ:COEPCoeptis Therapeutics Holdings Inc
08/11/202223:00PR Newswire (US)Coeptis Therapeutics' Scientific Advisory Board Members Featured on "Biology of Natural Killer (NK) Cells" PodcastNASDAQ:COEPCoeptis Therapeutics Holdings Inc
02/11/202222:00PR Newswire (US)Coeptis Therapeutics Holdings Expands Board of Directors with New AppointmentsNASDAQ:COEPCoeptis Therapeutics Holdings Inc
 Showing the most relevant articles for your search:NASDAQ:COEP

Your Recent History

ASX
XTO
S&P ASX 100
ASX
WDC
Westfield
NYSE
NKE
Nike
ASX
WES
Wesfarmers
COIN
ETHUSD
Ethereum
CCOM
SILVER
SILVER
NASDAQ
TSLA
Tesla
NYSE
MCD
McDonalds
FX
AUDCAD
AUD vs CAD
NASDAQ
AMZN
Amazon.com
NASDAQ
NVDA
NVIDIA
ASX
AMP
AMP
NYSE
JPM
JP Morgan Chase
FX
GBPAUD
Sterling vs AUD
ASX
WBC
Westpac Banking
FX
AUDUSD
AUD vs US Dollar
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved